Zum Inhalt springen

Jorge Barriuso

@drjorgebarriuso.bsky.social did:plc:la5yqfbrpcahwwqd3f75k4og

Consultant (clinician-scientist) in medical oncology with an interest in Lower GI malignancies including appendix tumours and peritoneal metastasis. #H12O #imas12 #rarecancers #translationalresearch #drugdevelopment

Bei Bluesky seit

Follower
51
Folgt
17
Posts
27
Tage in Ranglisten
0

Zusammenfassung

Jorge Barriuso (@drjorgebarriuso.bsky.social) ist seit 25 November 2024 auf Bluesky. Das Konto hat 51 Follower, folgt 17 Konten und hat 27 Posts veröffentlicht.

Ranglisten-Platzierungen

Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.

Dieses Konto war noch in keiner Tagesrangliste.

Zuletzt gelikte Posts

Öffentliche Likes aus dem Bluesky-Netzwerk.

  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Changing the cytotoxic payload may help to overcome resistance to antibody–drug conjugates (#ADCs). Rachel Abelman discusses studies investigating this strategy to improve patient responses in #BreastCancer #InsightsbyESMO ➡️ https://ow.ly/96mf5100brC

    Post anzeigen
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Early-phase #ClinicalTrial results with the novel bispecific antibodies, pumitamig and opamtistomig, reflect a growing body of research in #NeuroendocrineCarcinoma #InsightsbyESMO ➡️ https://ow.ly/oxLC5100p7J #NENs #NECs #RareCancers

    Post anzeigen
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    👉 #ESMONovelTherapies27: Novel therapies are changing oncology. Are you ready to optimise them in practice? -Understand the science -Select the right patients -Navigate treatment sequencing -Manage toxicities 🔗 https://ow.ly/vIkz50ZZAHh

    Post anzeigen
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger 🔗 https://ow.ly/6bmH5100p2M #InsightsbyESMO

    Post anzeigen
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50% ➡️ https://ow.ly/eWmC5100p3O #InsightsbyESMO Alfredo Addeo

    Post anzeigen

Melde dich an, um mehr zu sehen

Blockierte Konten

Blockierungen sind auf Bluesky öffentlich.

Dieses Konto blockiert niemanden.